G. Andriole

发表

Genome-wide association study of prostate cancer identifies a second risk locus at 8q24

P. Fearnhead, W. Willett, M. Thun, 2007, Nature Genetics.

Multiple loci identified in a genome-wide association study of prostate cancer

W. Willett, M. Thun, D. Gerhard, 2008, Nature Genetics.

Screening by chest radiograph and lung cancer mortality: the Prostate, Lung, Colorectal, and Ovarian (PLCO) randomized trial.

J. Gohagan, P. Prorok, B. Kramer, 2011, JAMA.

The MAPP research network: design, patient characterization and operations

Sean Mackey, David A. Williams, Dedra Buchwald, 2014, BMC Urology.

Is there a better way to biopsy the prostate? Prospects for a novel transrectal systematic biopsy approach.

Yan Yan, D. Bostwick, P. Humphrey, 2007, Urology.

Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up.

J. Gohagan, P. Prorok, B. Kramer, 2012, Journal of the National Cancer Institute.

Baseline prostate inflammation is associated with a reduced risk of prostate cancer in men undergoing repeat prostate biopsy: Results from the REDUCE study

G. Andriole, S. Freedland, D. Moreira, 2014, Cancer.

Smoking Is Associated with Acute and Chronic Prostatic Inflammation: Results from the REDUCE Study

G. Andriole, S. Freedland, D. Moreira, 2015, Cancer Prevention Research.

Measurement of prostate-specific antigen in serum as a screening test for prostate cancer.

W. Catalona, G. Andriole, Deborah S. Smith, 1991, The New England journal of medicine.

Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci

K. D. Sørensen, H. Ostrer, T. Sellers, 2018, Nature Genetics.

Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial.

J. Gohagan, P. Prorok, B. Kramer, 2011, JAMA.

Mortality results from a randomized prostate-cancer screening trial.

David Chia, Timothy R Church, Barnett S Kramer, 2009, The New England journal of medicine.

The MAPP research network: a novel study of urologic chronic pelvic pain syndromes

Dedra Buchwald, Daniel J Clauw, C. Heckman, 2014, BMC Urology.

Radical prostatectomy versus observation for localized prostate cancer.

Timothy J Wilt, Michael J Barry, Steven Fox, 2012, The New England journal of medicine.

NCCN Guidelines Insights: Prostate Cancer Early Detection, Version 2.2016.

Andrew J. Vickers, James L. Mohler, Geoffrey A. Sonn, 2016, Journal of the National Comprehensive Cancer Network : JNCCN.

Prostatectomy versus Observation for Early Prostate Cancer.

T. Wilt, G. Andriole, M. Brawer, 2017, The New England journal of medicine.

The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia.

C. Roehrborn, M. Menon, M. Lucia, 2003, The New England journal of medicine.

Three-Dimensional (3D) Vision: Does It Improve Laparoscopic Skills? An Assessment of a 3D Head-Mounted Visualization System.

G. Andriole, S. Bhayani, Gerald L Andriole, 2005, Reviews in urology.

Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants

Nawaid Usmani, Suzanne Chambers, Martin Eklund, 2018, Nature Communications.

Results From Four Rounds of Ovarian Cancer Screening in a Randomized Trial

Timothy R Church, Christine C Johnson, Edward Partridge, 2009, Obstetrics and gynecology.

A multi-stage genome-wide association study of bladder cancer identifies multiple susceptibility loci

William Wheeler, Tony Fletcher, Paolo Vineis, 2010, Nature Genetics.

New Frontiers in Patient-Reported Outcomes : Adverse Event Reporting , Comparative Effectiveness , and Quality Assessment

M. Gonzalez-Garay, G. Andriole, M. Vanstone, 2014 .

Using PSA to screen for prostate cancer. The Washington University experience.

W. Catalona, G. Andriole, 1993, The Urologic clinics of North America.

Do Margins Matter? The Influence of Positive Surgical Margins on Prostate Cancer–Specific Mortality: Stephenson AJ, Eggener SE, Hernandez AV, et al (Cleveland Clinic, OH; Univ of Chicago Med Ctr, IL; et al) Eur Urol 65:675-680, 2014 §

G. Andriole, 2014 .

The Accuracy of Prostate Magnetic Resonance Imaging Interpretation: Impact of the Individual Radiologist and Clinical Factors.

G. Andriole, J. Ippolito, A. Shetty, 2019, Urology.

Accuracy and Variability of Prostate Multiparametric Magnetic Resonance Imaging Interpretation Using the Prostate Imaging Reporting and Data System: A Blinded Comparison of Radiologists.

Kathryn J Fowler, G. Andriole, A. Shetty, 2020, European urology focus.

Magnetic resonance imaging-targeted vs. conventional transrectal ultrasound-guided prostate biopsy: single-institution, matched cohort comparison.

Kathryn J Fowler, G. Andriole, Michael H. Johnson, 2015, Urologic oncology.

Prostate cancer gene 3 score predicts prostate biopsy outcome in men receiving dutasteride for prevention of prostate cancer: results from the REDUCE trial.

G. Andriole, R. Rittmaster, J. Groskopf, 2011, Urology.

PCA3 molecular urine test for predicting repeat prostate biopsy outcome in populations at risk: validation in the placebo arm of the dutasteride REDUCE trial.

G. Andriole, R. Rittmaster, J. Groskopf, 2010, The Journal of urology.

13-Year Outcomes Following Treatment for Clinically Localized Prostate Cancer in a Population Based Cohort

G. Andriole, 2007 .

Statin Use and Lower Urinary Tract Symptoms Incidence and Progression in Reduction by Dutasteride of Prostate Cancer Events (REDUCE) Trial

I. Csizmadi, G. Andriole, S. Freedland, 2021, The Journal of urology.

The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group.

C. Roehrborn, G. Andriole, P. Walsh, 1998, The New England journal of medicine.

The effect of finasteride in men with benign prostatic hyperplasia. 1992.

G. Andriole, P. Walsh, E. Vaughan, 2002, The Journal of urology.

Early complications of contemporary anatomical radical retropubic prostatectomy.

W. Catalona, G. Andriole, Deborah S. Smith, 1994, The Journal of urology.

The natural history, skeletal complications, and management of bone metastases in patients with prostate carcinoma

G. Andriole, B I Carlin, G L Andriole, 2000, Cancer.

Serum prostate specific antigen is a strong predictor of future prostate growth in men with benign prostatic hyperplasia. PROSCAR long-term efficacy and safety study.

P. Schellhammer, C. Roehrborn, M. Resnick, 2000, The Journal of urology.

11C-Acetate PET/CT Before Radical Prostatectomy: Nodal Staging and Treatment Failure Prediction

A. Kibel, T. Miller, G. Andriole, 2013, The Journal of Nuclear Medicine.

THE EFFECTS OF 5α-REDUCTASE INHIBITORS ON THE NATURAL HISTORY, DETECTION AND GRADING OF PROSTATE CANCER: CURRENT STATE OF KNOWLEDGE

D. Bostwick, C. Roehrborn, M. Lucia, 2005 .

Multicenter, randomized, double-blind, placebo controlled study to investigate the effect of finasteride (MK-906) on stage D prostate cancer.

G. Andriole, W. Fair, P. Sogani, 1992, The Journal of urology.

Prostate specific antigen based prostate cancer screening: accumulating evidence of efficacy but persistent uncertainty.

G. Andriole, 2005, The Journal of urology.

Value of Targeted Prostate Biopsy Using Magnetic Resonance–Ultrasound Fusion in Men with Prior Negative Biopsy and Elevated Prostate-Specific Antigen: Sonn GA, Chang E, Natarajan S, et al (Univ of California, Los Angeles) Eur Urol 65:809-815, 2014 §

G. Andriole, G. L. Andriole, 2014 .

Statin use and risk of prostate cancer and high-grade prostate cancer: results from the REDUCE study

G. Andriole, S. Freedland, D. Moreira, 2013, Prostate Cancer and Prostatic Diseases.

Body size throughout the life-course and incident benign prostatic hyperplasia-related outcomes and nocturia

G. Andriole, L. Ragard, K. Wolin, 2021, BMC Urology.

Obesity is associated with increased prostate growth and attenuated prostate volume reduction by dutasteride.

G. Andriole, S. Freedland, D. Moreira, 2013, European urology.

Gonorrhea, Syphilis, Clinical Prostatitis, and the Risk of Prostate Cancer

G. Andriole, 2007 .

Electronic nutritional intake assessment in patients with urolithiasis: A decision impact analysis

G. Andriole, L. McIntosh, A. Potretzke, 2016, Investigative and clinical urology.

Metabolic syndrome‐like components and prostate cancer risk: results from the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) study

G. Andriole, S. Freedland, D. Moreira, 2015, BJU international.

Factors associated with higher prostate biopsy yield: when is software-assisted fusion MRI-targeting necessary?

G. Andriole, I. Kim, Eric H Kim, 2020, Urologic oncology.

Chemoprevention of prostate cancer.

G. Andriole, S. Freedland, R. Hamilton, 2014, Annual review of medicine.

Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019.

Anne E. Calvaresi, P. Carroll, A. M. López, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Imputation and subset-based association analysis across different cancer types identifies multiple independent risk loci in the TERT-CLPTM1L region on chromosome 5p15.33.

William Wheeler, Hideo Tanaka, Jianxin Shi, 2014, Human molecular genetics.

Flexible sigmoidoscopy in the randomized prostate, lung, colorectal, and ovarian (PLCO) cancer screening trial: added yield from a second screening examination.

P. Prorok, J. Rathmell, E. Crawford, 2012, Journal of the National Cancer Institute.

History of Prostate-Specific Antigen, from Detection to Overdiagnosis

G. Andriole, B. Manley, 2016 .

Prostate-specific antigen-based risk assessment in younger men.

G. Andriole, S. Strope, 2012, European urology.

Comorbidity and mortality results from a randomized prostate cancer screening trial.

A. D'Amico, Ming-Hui Chen, E. Crawford, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Common 8 q 24 Variant in Prostate and Breast Cancer from a Large Nested Case-Control Study

W. Willett, M. Pike, M. Thun, 2007 .

Prospective evaluation of serum sarcosine and risk of prostate cancer in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial.

Tamra E. Meyer, R. Hoover, T. Veenstra, 2013, Carcinogenesis.

Cost effectiveness of chemoprevention for prostate cancer with dutasteride in a high-risk population based on results from the REDUCE Clinical trial

M. Kattan, G. Andriole, L. Black, 2011, Applied health economics and health policy.

Prostate Magnetic Resonance Imaging Provides Limited Incremental Value Over the Memorial Sloan Kettering Cancer Center Preradical Prostatectomy Nomogram.

G. Andriole, S. Strope, R. Grubb, 2017, Urology.

Update of the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.

G. Andriole, 2014, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

Mortality and complications after prostate biopsy in the Prostate, Lung, Colorectal and Ovarian Cancer Screening (PLCO) trial

H. Parnes, G. Andriole, P. Pinsky, 2014, BJU international.

Obesity Increases the Risk for High-Grade Prostate Cancer: Results from the REDUCE Study

G. Andriole, S. Freedland, D. Moreira, 2014, Cancer Epidemiology, Biomarkers & Prevention.

Active surveillance for prostate cancer: barriers to widespread adoption.

G. Andriole, G. Sandhu, 2012, European urology.

Does Obesity Modify the Ability of Prebiopsy Prostate Specific Antigen to Detect Prostate Cancer on Repeat Biopsy? Results from the REDUCE Study.

G. Andriole, S. Freedland, D. Moreira, 2015, The Journal of urology.

Cost-effectiveness of prostate specific antigen screening in the United States: extrapolating from the European study of screening for prostate cancer.

G. Andriole, A. Shteynshlyuger, 2011, The Journal of urology.

Systematic Review of Complications of Prostate Biopsy: Loeb S, Vellekoop A, Ahmed HU, et al (New York Univ; Univ College London, UK; et al) Eur Urol 64:876-892, 2013 §

G. Andriole, 2014 .

Sexually transmitted infections, benign prostatic hyperplasia and lower urinary tract symptomrelated outcomes: results from the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial

Sutcliffe, G. Andriole, L. Ragard, 2015 .

Surgeon variation in patient quality of life after radical prostatectomy.

D. R. Cutler, G. Andriole, S. Strope, 2013, Journal of Urology.

Treatment with finasteride preserves usefulness of prostate-specific antigen in the detection of prostate cancer: results of a randomized, double-blind, placebo-controlled clinical trial. PLESS Study Group. Proscar Long-term Efficacy and Safety Study.

E. Crawford, G. Andriole, J. Epstein, 1998, Urology.

Variability in Outcomes for Patients with Intermediate-risk Prostate Cancer (Gleason Score 7, International Society of Urological Pathology Gleason Group 2-3) and Implications for Risk Stratification: A Systematic Review.

G. Andriole, C. Kane, S. Eggener, 2017, European urology focus.

Surgically managed lymph node-positive prostate cancer: does delaying hormonal therapy worsen the outcome?: Spiess PE, Lee AK, Busby JE, et al (Univ of Texas, Houston) BJU Int 99:321–325, 2006 §

G. Andriole, 2007 .

Sonographic and pathological staging of patients with clinically localized prostate cancer.

W. Catalona, G. Andriole, D. Coplen, 1989, The Journal of urology.

Prostate Cancer Review.

G. Andriole, Eric H Kim, Eric H. Kim, 2018, Missouri medicine.

Physical Activity and Benign Prostatic Hyperplasia-Related Outcomes and Nocturia

G. Andriole, L. Ragard, K. Wolin, 2015, Medicine and science in sports and exercise.

452 ASSESSING THE FEASIBILITY OF ELECTRONIC DATA COLLECTION FOR MEN WITH PROSTATE CANCER

G. Andriole, L. McIntosh, Elizabeth Jones, 2013 .

Should men undergo MRI before prostate biopsy - CON.

G. Andriole, Eric H Kim, Eric H. Kim, 2021, Urologic oncology.

Prospective Randomized Comparison of Cutting and Dilating Disposable Trocars for Access During Laparoscopic Renal Surgery

R. Clayman, G. Andriole, C. Sundaram, 2007, JSLS : Journal of the Society of Laparoendoscopic Surgeons.

Individualized Estimates of Overdiagnosis in Screen-Detected Prostate Cancer

G. Andriole, 2014 .

Urinary Metabolomics Identifies a Molecular Correlate of Interstitial Cystitis/Bladder Pain Syndrome in a Multidisciplinary Approach to the Study of Chronic Pelvic Pain (MAPP) Research Network Cohort

M. Lucia, J. Crowley, G. Andriole, 2016, EBioMedicine.

Relationship between chronic nonurological associated somatic syndromes and symptom severity in urological chronic pelvic pain syndromes: baseline evaluation of the MAPP study.

David A. Williams, Kevin A. Johnson, K. A. Scott, 2015, The Journal of urology.

Integrating the Genomic Prostate Score into Clinical Practice Workflow

G. Andriole, D. Albala, S. Canfield, 2016, Urology practice.

Aspirin, NSAIDs, and Risk of Prostate Cancer: Results from the REDUCE Study

G. Andriole, S. Freedland, D. Moreira, 2014, Clinical Cancer Research.

Dietary protein restriction reduces circulating VLDL triglyceride levels via CREBH-APOA5-dependent and -independent mechanisms.

G. Andriole, N. Veronese, L. Brace, 2018, JCI insight.

Magnetic Resonance Imaging-Defined Prostate-Specific Antigen Density Significantly Improves the Risk Prediction for Clinically Significant Prostate Cancer on Biopsy.

G. Andriole, J. Ippolito, A. Shetty, 2019, Urology.

Diagnostic performance of prostate multiparametric magnetic resonance imaging in African-American men.

G. Andriole, J. Ippolito, B. Drake, 2019, Urology.

Improved Detection of Clinically Significant Prostate Cancer With Software-assisted Systematic Biopsy Using MR/US Fusion in Patients With Negative Prostate MRI.

Kathryn J Fowler, G. Andriole, Y. Meng, 2018, Urology.

Modified Gleason grade of prostatic adenocarcinomas detected in the PLCO cancer screening trial.

P. Humphrey, G. Andriole, T. Riley, 2014, The Journal of urology.

Modeling and analysis of Gleason score 8-10 prostate cancers in the REDUCE study.

D. Tindall, D. Bostwick, T. Tammela, 2014, Urology.

Active Surveillance for the Management of Prostate Cancer in a Contemporary Cohort: Dall'Era MA, Konety BR, Cowan JE, et al (Univ of California at San Francisco; et al) Cancer 112:2664-2670, 2008 §

G. Andriole, 2012 .

Magnetic Resonance Imaging Provides Added Value to the Prostate Cancer Prevention Trial Risk Calculator for Patients With Estimated Risk of High-grade Prostate Cancer Less Than or Equal to 10.

G. Andriole, S. Strope, A. Shetty, 2017, Urology.

Improving the early detection of prostate cancer: a balancing act.

G. Andriole, J. Brockman, 2014, Oncology.

Prostate cancer: Improvements in risk stratification of prostate cancer

G. Andriole, G. Sandhu, 2013, Nature Reviews Urology.

Bad habits may be hard to break.

G. Andriole, G. Vemana, 2013, European urology.

Lung cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.

David A Lynch, John K Gohagan, Carl R Fuhrman, 2010, Journal of the National Cancer Institute.

Cumulative Incidence of False-Positive Results in Repeated, Multimodal Cancer Screening

J. Gohagan, B. Kramer, E. Crawford, 2009, The Annals of Family Medicine.

The impact of prostate cancer and hormonal therapy on bone.

G. Andriole, 2009, Reviews in urology.

Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial.

P C Prorok, J L Weissfeld, J. Gohagan, 2000, Controlled clinical trials.

Projecting prostate cancer mortality in the PCPT and REDUCE chemoprevention trials

H. Parnes, E. Crawford, G. Andriole, 2013, Cancer.

Non‐steroidal anti‐inflammatory drug use and the risk of benign prostatic hyperplasia‐related outcomes and nocturia in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial

R. Hayes, G. Andriole, E. Platz, 2012, BJU international.

Supplemental and dietary vitamin E, beta-carotene, and vitamin C intakes and prostate cancer risk.

R. Hayes, N. Chatterjee, S. Mayne, 2006, Journal of the National Cancer Institute.

5α-Reductase Inhibitors and Chemoprevention: The PCPT and Beyond

G. Andriole, 2006 .

Association of Obesity‐Related Hemodilution of Prostate‐Specific Antigen, Dihydrotestosterone, and Testosterone

M. Terris, G. Andriole, S. Freedland, 2017, The Prostate.

An asterisk indicates reviewers who have evaluated three or more manuscripts in 2012.

David Ball, Ash A. Alizadeh, David A. August, 2013 .

Systemic Non-Urologic Symptoms in Patients with Overactive Bladder

G. Andriole, J. Vetter, H. H. Lai, 2016 .

Systemic Nonurological Symptoms in Patients with Overactive Bladder.

G. Andriole, H. Lai, Sanjay Jain, 2016, The Journal of urology.

Correlation between psychological stress levels and the severity of overactive bladder symptoms

G. Andriole, H. Lai, J. Vetter, 2015, BMC Urology.

Prostate Cancer Incidence and Mortality Following a Negative Biopsy in a Population Undergoing PSA Screening.

H. Parnes, G. Andriole, P. Pinsky, 2021, Urology.

Low Penetrance Germline Genetic Testing: Role for Risk Stratification in Prostate Cancer Screening and Examples From Clinical Practice.

G. Andriole, C. Kane, A. Kader, 2020, Reviews in urology.

Extended follow‐up for prostate cancer incidence and mortality among participants in the Prostate, Lung, Colorectal and Ovarian randomized cancer screening trial

Eric A. Miller, P. Prorok, E. Crawford, 2018, BJU international.

Prostate cancer chemoprevention with 5α-reductase inhibitors.

G. Andriole, K. Nepple, 2012, Urologic oncology.

Editorial for “prediction of significant prostate cancer diagnosed 20 to 30 years later with a single measure of prostate‐specific antigen at or before age 50”

A. Kibel, G. Andriole, 2011, Cancer.

Screening for prostate cancer.

G. Andriole, 2010, BMJ.

A framework for the identification of men at increased risk for prostate cancer.

G. Andriole, M. Roobol, F. Schröder, 2009, The Journal of urology.

Clinical judgment versus biomarker prostate cancer gene 3: which is best when determining the need for repeat prostate biopsy?

A. Haese*, G. Andriole, M. Remzi, 2013, Urology.

Baseline Prostate Atrophy is Associated with Reduced Risk of Prostate Cancer in Men Undergoing Repeat Prostate Biopsy.

H. Cohen, D. Bostwick, G. Andriole, 2015, The Journal of urology.

Use of Medical Therapy and Success of Laser Surgery and Transurethral Resection of the Prostate for Benign Prostatic Hyperplasia.

G. Andriole, M. Olsen, S. Elliott, 2015, Urology.

Relationship of demographic and clinical factors to free and total prostate-specific antigen.

J. Gohagan, R. Hayes, B. Kramer, 2001, Urology.

Prevention and early detection of prostate cancer.

Timothy J Wilt, Dragan Ilic, Jack Cuzick, 2014, The Lancet. Oncology.

Usefulness of prostate‐specific antigen (PSA) rise as a marker of prostate cancer in men treated with dutasteride: lessons from the REDUCE study

F. Montorsi, G. Andriole, S. Freedland, 2012, BJU international.

Projecting Prostate Cancer Mortality in the PCPT and REDUCE Chemoprevention Trials: Pinsky PF, Black A, Grubb R, et al (Natl Cancer Inst, Bethesda, MD; Washington Univ, St Louis, MO; et al) Cancer 119:593-601, 2013 §

G. Andriole, 2013 .

Chemoprevention of prostate cancer in men at high risk: rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trial.

D. Tindall, D. Bostwick, G. Andriole, 2004, The Journal of urology.

Radical Prostatectomy or Watchful Waiting in Early Prostate Cancer: Bill-Axelson A, Holmberg L, Garmo H, et al (Uppsala Univ Hosp, Sweden; et al) N Engl J Med 370:932-942, 2014 §

G. Andriole, 2014 .

Update on chemoprevention for prostate cancer

G. Andriole, S. Strope, 2010, Current opinion in urology.

Survival Outcomes in Men with Unfavorable Intermediate-Risk and High-Risk Prostate Cancer Treated with Prostate-Only versus Whole Pelvic Radiation Therapy

G. Andriole, H. Gay, N. Andruska, 2022, The Journal of urology.

Serum prostate-specific antigen: the most useful tumor marker.

G. Andriole, 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prostate-Specific Antigen Levels as a Predictor of Lethal Prostate Cancer

G. Andriole, 2007 .

Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials

E. Feuer, H. D. de Koning, Ruth Etzioni, 2017, Annals of Internal Medicine.

The use of 5-alpha reductase inhibitors in the treatment of benign prostatic hyperplasia

G. Andriole, Eric H Kim, Eric H. Kim, 2017, Asian journal of urology.

The association of atrophy in baseline prostate biopsy and lower prostate cancer grade in radical prostatectomy specimens

G. Andriole, S. Freedland, D. Moreira, 2018, Scandinavian journal of urology.

Alcohol intake increases high-grade prostate cancer risk among men taking dutasteride in the REDUCE trial.

G. Andriole, S. Freedland, J. Fowke, 2014, European urology.

Dutasteride and Prostate Cancer Risk: Does Family History of Prostate and/or Breast Cancers Influence the Number Needed to Treat? Results from REDUCE

G. Andriole, S. Freedland, D. Moreira, 2014 .

5α-reductase inhibitors: preventing the treatable.

G. Andriole, S. Freedland, R. Hamilton, 2012, European urology.

Effect of dutasteride on prostate biopsy rates and the diagnosis of prostate cancer in men with lower urinary tract symptoms and enlarged prostates in the Combination of Avodart and Tamsulosin trial.

C. Roehrborn, G. Andriole, R. Rittmaster, 2011, European urology.

Reduction in the risk of prostate cancer: future directions after the Prostate Cancer Prevention Trial.

E. Crawford, G. Andriole, M. Marberger, 2010, Urology.

Redesigning a large-scale clinical trial in response to negative external trial results: the CAMUS study of Phytotherapy for Benign Prostatic Hyperplasia

C. Roehrborn, E. Crawford, G. Andriole, 2009, Clinical trials.

Benign prostatic hyperplasia: Current treatment strategies

G. Andriole, Tyler L. Christensen, 2009 .

High-grade prostate cancer in the Prostate Cancer Prevention Trial: fact or artifact?

R. Serfling, P. Humphrey, G. Andriole, 2007, Journal of the National Cancer Institute.

Effect of dutasteride on the detection of prostate cancer in men with benign prostatic hyperplasia.

G. Andriole, C. Roehrborn, K. Slawin, 2004, Urology.

Dutasteride: profile report

G. Andriole, J. Nickel, 2012 .

Effect of the dual 5alpha-reductase inhibitor dutasteride on markers of tumor regression in prostate cancer.

M. Gleave, J. Trachtenberg, G. Andriole, 2004, The Journal of urology.

Improved biopsy efficiency with MR/ultrasound fusion-guided prostate biopsy.

G. Andriole, Eric H Kim, Eric H. Kim, 2016, Journal of the National Cancer Institute.

Lifetime Implications and Cost-effectiveness of Using Finasteride to Prevent Prostate Cancer

G. Andriole, 2006 .

Asian Race and Risk of Prostate Cancer: Results from the REDUCE Study

G. Andriole, S. Freedland, D. Moreira, 2020, Cancer Epidemiology, Biomarkers & Prevention.

Replication of Five Prostate Cancer Loci Identified in an Asian Population—Results from the NCI Breast and Prostate Cancer Cohort Consortium (BPC3)

W. Willett, S. Chanock, D. Hunter, 2011, Cancer Epidemiology, Biomarkers & Prevention.

Sequence Variants of Estrogen Receptor β and Risk of Prostate Cancer in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium

D. Altshuler, M. Pike, J. Hirschhorn, 2007, Cancer Epidemiology Biomarkers & Prevention.

Re: Chronic Baseline Prostate Inflammation is Associated with Lower Tumor Grade in Men with Prostate Cancer on Repeat Biopsy: Results from the REDUCE Study.

G. Andriole, S. Freedland, D. Moreira, 2020, The Journal of urology.

Prostate cancer screening in the Prostate, Lung, Colorectal and Ovarian cancer screening trial: update on findings from the initial four rounds of screening in a randomized trial

J. Gohagan, P. Prorok, B. Kramer, 2008, BJU international.

The effect of dutasteride on the usefulness of prostate specific antigen for the diagnosis of high grade and clinically relevant prostate cancer in men with a previous negative biopsy: results from the REDUCE study.

D. Tindall, D. Bostwick, T. Tammela, 2011, The Journal of urology.

Dutasteride is associated with reduced risk of transrectal prostate biopsy-associated urinary tract infection and related hospitalizations

C. Roehrborn, G. Andriole, S. Freedland, 2017, World Journal of Urology.

Long-Term Functional Outcomes after Treatment for Localized Prostate Cancer

G. Andriole, 2013 .

Seven prostate cancer susceptibility loci identified by a multi-stage genome-wide association study

Suzanne Chambers, Peter Kraft, Henrik Gronberg, 2011, Nature Genetics.

Defining increased future risk for prostate cancer: evidence from a population based screening cohort.

G. Andriole, M. Roobol, F. Schröder, 2009, The Journal of urology.

Who is best benefited by radical prostatectomy?

G. Andriole, R. Nadler, R. B. Nadler, 1996, Hematology/oncology clinics of North America.

Comparison of percent free prostate-specific antigen levels in men with benign prostatic hyperplasia treated with finasteride, terazosin, or watchful waiting.

W. Catalona, G. Andriole, T. Ratliff, 1998, Urology.

Radical Prostatectomy for Prostate Cancer

G. Andriole, 1994 .

Laparoscopic radical prostatectomy: CON.

G. Andriole, 2001, Urology.

Urological chronic pelvic pain syndrome symptom flares: characterisation of the full range of flares at two sites in the Multidisciplinary Approach to the Study of Chronic Pelvic Pain (MAPP) Research Network

G. Colditz, G. Andriole, T. Ness, 2014, BJU international.

Biochemical response to testicular androgen ablation among patients with prostate cancer for whom flutamide and/or finasteride therapy failed.

D. Ornstein, G. Andriole, Deborah S. Smith, 1998, Urology.

Early diagnosis of prostate cancer.

W. Catalona, G. Andriole, 1987, The Urologic clinics of North America.

The diagnosis and treatment of prostate cancer.

W. Catalona, G. Andriole, 1991, Annual review of medicine.

Saturation biopsies on autopsied prostates for detecting and characterizing prostate cancer

G. Andriole, 2009 .

Diagnostic properties of total and free prostate-specific antigen to predict overall and clinically significant prostate cancer among men with low testosterone and prior negative biopsy.

G. Andriole, S. Freedland, D. Moreira, 2019, Urology.

Decreased Consumption o f Branched-Chain Amino Acids Improves Metabolic Health Graphical

Faizan A. Syed, Emma L. Baar, Dudley Lamming, 2016 .

Decreased Consumption of Branched-Chain Amino Acids Improves Metabolic Health.

S. A. Arriola Apelo, Faizan A. Syed, Emma L. Baar, 2016, Cell reports.

Serum testosterone and dihydrotestosterone and prostate cancer risk in the placebo arm of the Reduction by Dutasteride of Prostate Cancer Events trial.

G. Andriole, S. Freedland, D. Moreira, 2012, European urology.

Pathology: The lottery of conventional prostate biopsy

G. Andriole, 2009, Nature Reviews Urology.

Human prostate carcinoma causes hypercalcemia in athymic nude mice and produces a factor with parathyroid hormone-like bioactivity.

W. Linehan, G. Andriole, A. Santora, 1986, The Journal of urology.

Benign prostatic hyperplasia: a progressive disease of aging men.

C. Roehrborn, G. Andriole, M. Emberton, 2003, Urology.

Office-based transurethral microwave thermotherapy using the TherMatrx TMx-2000.

J. Lingeman, G. Andriole, D. Albala, 2002, Journal of endourology.

Appropriate Patient Selection in the Focal Treatment of Prostate Cancer: The Role of Transperineal 3-Dimensional Pathologic Mapping of the Prostate—A 4-Year Experience: Barzell WE, Melamed MR (Urology Treatment Ctr, Sarasota, FL; New York Med College, Valhalla) Urology 70:27-35, 2007 §

G. Andriole, 2012 .

Image-Guided Prostate Biopsy Using Magnetic Resonance Imaging–Derived Targets: A Systematic Review: Moore CM, Robertson NL, Arsanious N, et al (Univ College London, UK; Croydon Univ Hosp, London, UK; et al) Eur Urol 63:125-140, 2013 §

G. Andriole, 2013 .

Long-term 6-year experience with finasteride in patients with benign prostatic hyperplasia.

M. Lieber, M. Elhilali, G. Andriole, 2003, Urology.

T-cell subsets required for intravesical BCG immunotherapy for bladder cancer.

W. Catalona, G. Andriole, T. Ratliff, 1993, The Journal of urology.

Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia.

P. Boyle, C. Roehrborn, G. Andriole, 2002, Urology.

Long-Term Prediction of Prostate Cancer Up to 25 Years Before Diagnosis of Prostate Cancer Using Prostate Kallikreins Measured at Age 44 to 50 Years

G. Andriole, 2007 .

Statin use and longitudinal changes in prostate volume; results from the REduction by DUtasteride of prostate Cancer Events (REDUCE) trial

I. Csizmadi, C. Roehrborn, G. Andriole, 2019, BJU International.

Corrigendum to Fine-mapping identifies multiple prostate cancer risk loci at 5p15, one of which associates with TERT expression [Human Molecular Genetics, 22, (2013), 2520-2528] doi: 10.1093/hmg/ddt086

D. Schaid, H. Brenner, E. Riboli, 2013 .

Serum cholesterol and risk of lower urinary tract symptoms progression: Results from the Reduction by Dutasteride of Prostate Cancer Events study

G. Andriole, S. Freedland, D. Moreira, 2017, International journal of urology : official journal of the Japanese Urological Association.

Early results with antegrade collagen injection for post-radical prostatectomy stress urinary incontinence.

G. Andriole, R. Nadler, D. Tiemann, 1996, The Journal of urology.

Antegrade collagen injection for stress incontinence after radical prostatectomy: technique and early results.

G. Andriole, R. Nadler, D. Tiemann, 1996, Journal of endourology.

Chronic baseline prostate inflammation is associated with lower tumor volume in men with prostate cancer on repeat biopsy: Results from the REDUCE study

G. Andriole, S. Freedland, D. Moreira, 2015, The Prostate.

Life imitates art.

G. Andriole, D. Jablons, 2020, Pennsylvania medicine.

1151: Perioperative Quality Care Indicators of Retropubic, Laparoscopic, and Robotic Prostatectomy: Results from a National, Multi-Center, Prospective Cohort

John T. Wei, A. Kibel, Jim C Hu, 2006 .

Treatment with finasteride following radical prostatectomy for prostate cancer.

G. Andriole, D. Kadmon, M. Soloway, 1995, Urology.

Combined finasteride and flutamide therapy in men with advanced prostate cancer.

D. Ornstein, G. Andriole, G. Rao, 1996, Urology.

The impact of smoking on sexual function

G. Andriole, S. Freedland, D. Moreira, 2022, BJU international.

Surgical treatment of renal neoplasia: evolving toward a laparoscopic standard of care.

R. Clayman, A. Kibel, A. Shalhav, 2003, Urology.

Prostate cancer recurrence in patients with negative or equivocal conventional imaging: A role for 18F-fluciclovine-PET/CT in delineating sites of recurrence and identifying patients with oligometastatic disease.

G. Andriole, B. Siegel, E. Teoh, 2020, Urologic oncology.

Population Based Study of Hormonal Therapy and Survival in Men With Metastatic Prostate Cancer

G. Andriole, 2007 .

Risk of urinary incontinence following prostatectomy: the role of physical activity and obesity.

A. Kibel, G. Andriole, K. Wolin, 2010, The Journal of urology.

Anaemia in men receiving combined finasteride and flutamide therapy for advanced prostate cancer

D. Ornstein, J. Beiser, G. Andriole, 1999, BJU international.

The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group.

R C Bruskewitz, G. Andriole, P. Walsh, 2002, The New England journal of medicine.

Safety and Tolerability of the Dual 5α-Reductase Inhibitor Dutasteride in the Treatment of Benign Prostatic Hyperplasia

G. Andriole, R. Kirby, 2003 .

Body Mass Index, Prostate-Specific Antigen, and Digital Rectal Examination Findings Among Participants in a Prostate Cancer Screening Clinic

G. Andriole, 2008 .

Replication of Five Prostate Cancer Loci Identi ﬁ ed in an Asian Population — Results from the NCI Breast and Prostate Cancer Cohort Consortium (BPC3) Epidemiology,Biomarkers&Prevention

S. Chanock, B. Henderson, C. Haiman, 2011 .

Urologic Symptoms of a subset of urologic chronic pelvic pain syndrome (UCPPS) patients with a poly-symptomatic, polysyndromic pattern of presentation

G. Andriole, B. Hong, C. North, 2015 .

Urological symptoms in a subset of patients with urological chronic pelvic pain syndrome and a polysymptomatic, polysyndromic pattern of presentation.

G. Andriole, T. Ness, H. Lai, 2014, The Journal of urology.

Polysymptomatic, polysyndromic presentation of patients with urological chronic pelvic pain syndrome.

G. Andriole, H. Lai, B. Hong, 2012, The Journal of urology.

MR imaging of benign prostatic hypertrophy using a Helmholtz-type surface coil.

G. Andriole, J. Lee, J. Brown, 1992, Magnetic resonance imaging.

Commentary RE: "Efficacy and Safety of a Dual Inhibitor of 5-Alpha-Reductase Types 1 and 2 (Dutasteride) in Men with Benign Prostatic Hyperplasia".

G. Andriole, Eric H Kim, Eric H. Kim, 2020, Urology.

Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial.

G. Andriole, Y. Lotan, S. Boorjian, 2020, The Lancet. Oncology.

PCA3: A Molecular Urine Assay for Predicting Prostate Biopsy Outcome

G. Andriole, 2009 .

Maximal testosterone suppression in prostate cancer--free vs total testosterone.

E. Crawford, G. Andriole, P. Lange, 2014, Urology.

A Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer at Initial Biopsy.

John T. Wei, P. Carroll, M. Kattan, 2016, JAMA oncology.

MP40-10 EXTENDED VALIDATION RESULTS FROM A PROSPECTIVE ADAPTIVE UTILITY TRIAL CONFIRM PERFORMANCE OF A NOVEL URINE EXOSOME GENE EXPRESSION ASSAY TO PREDICT HIGH-GRADE PROSTATE CANCER AT INITIAL BIOPSY

P. Carroll, G. Andriole, A. Partin, 2018 .

Are changes in US practices for androgen deprivation therapy financially motivated?

G. Andriole, M. Katz, 2008, Nature Clinical Practice Urology.

The efficacy of mesna (2-mercaptoethane sodium sulfonate) as a uroprotectant in patients with hemorrhagic cystitis receiving further oxazaphosphorine chemotherapy.

G. Andriole, I. Magrath, J. Miser, 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Hemodilution of Prostate-Specific Antigen Levels Among Obese Men

G. Andriole, R. Grubb, 2009 .

Does weather trigger urologic chronic pelvic pain syndrome flares? A case‐crossover analysis in the multidisciplinary approach to the study of the chronic pelvic pain research network

G. Colditz, G. Andriole, L. Dennis, 2020, Neurourology and urodynamics.

Multiparametric Magnetic Resonance Imaging and Ultrasound Fusion Biopsy Detect Prostate Cancer in Patients with Prior Negative Transrectal Ultrasound Biopsies: Vourganti S, Rastinehad A, Yerram NK, et al (Natl Cancer Inst, Bethesda, MD; et al) J Urol 188:2152-2157, 2012 §

G. Andriole, 2013 .

Effect of dutasteride on prostate biopsy rates and the diagnosis of prostate cancer in men with lower urinary tract symptoms and enlarged prostates in the combination of avodart and tamsulosin trial

C. Roehrborn, G. Andriole, R. Rittmaster, 2011 .

Genome-wide association study identifies new prostate cancer susceptibility loci.

M. Thun, H. Grönberg, R. Hayes, 2011, Human molecular genetics.

A propensity analysis comparing definitive chemo-radiotherapy for muscle-invasive squamous cell carcinoma of the bladder vs. urothelial carcinoma of the bladder using the National Cancer Database

G. Andriole, V. Arora, J. Michalski, 2018, Clinical and translational radiation oncology.

Vesicourethral dysfunction following pelvic visceral ablative surgery.

G. Andriole, S. Yalla, 1984, The Journal of urology.

Words of wisdom. Re: A prospective, blinded comparison of magnetic resonance (MR) imaging-ultrasound fusion and visual estimation in the performance of MR-targeted prostate biopsy: the PROFUS trial.

G. Andriole, Michael H. Johnson, Eric H Kim, 2014, European urology.

The effect of 4MA, a potent inhibitor of 5 alpha‐reductase, on the growth of androgen‐responsive human genitourinary tumors grown in athymic nude mice

W. M. Linehan, G. Andriole, R. Rittmaster, 1987, The Prostate.

The Multidisciplinary Approach to The Study of Chronic Pelvic Pain (MAPP) Research Network*: Design and implementation of the Symptom Patterns Study (SPS)

David A. Williams, M. Pontari, M. Lucia, 2020, Neurourology and urodynamics.

Changes in whole body pain intensity and widespreadness during urologic chronic pelvic pain syndrome flares—Findings from one site of the MAPP study

G. Colditz, G. Andriole, B. Naliboff, 2019, Neurourology and urodynamics.

Changes in symptoms during urologic chronic pelvic pain syndrome symptom flares: Findings from one site of the MAPP Research Network

G. Colditz, G. Andriole, C. Bradley, 2015, Neurourology and urodynamics.

The overlap and distinction of self-reported symptoms between interstitial cystitis/bladder pain syndrome and overactive bladder: a questionnaire based analysis.

G. Andriole, H. Lai, Sanjay Jain, 2014, The Journal of urology.

Final Results of a Phase I/II Multicenter Trial of WST11 (TOOKAD ® Soluble) Vascular-Targeted Photodynamic Therapy (VTP) for Hemiablation of the Prostate in Men with Unilateral Low Risk Prostate Cancer Conducted in the United States

G. Andriole, J. Coleman, S. Taneja, 2017 .

Group consensus reports from the Consensus Conference on Focal Treatment of Prostatic Carcinoma, Celebration, Florida, February 24, 2006.

D. Bostwick, G. Andriole, J. Rewcastle, 2007, Urology.

PSA predicts development of incident lower urinary tract symptoms: results from the REDUCE study

C. Roehrborn, G. Andriole, S. Freedland, 2018, Prostate Cancer and Prostatic Diseases.

Prostate-specific antigen as a screening test for prostate cancer : The United States experience : Prostate-specific antigen: the best prostatic tumor marker

D. Ornstein, G. Andriole, D. Keetch, 1997 .

Do the Benefits of Finasteride Outweigh the Risks in the Prostate Cancer Prevention Trial

G. Andriole, 2006 .

The effects of 5alpha-reductase inhibitors on the natural history, detection and grading of prostate cancer: current state of knowledge.

D. Bostwick, C. Roehrborn, M. Lucia, 2005, Journal of Urology.

Dutasteride improves outcomes of benign prostatic hyperplasia when evaluated for prostate cancer risk reduction: secondary analysis of the REduction by DUtasteride of prostate Cancer Events (REDUCE) trial.

C. Roehrborn, G. Andriole, J. Nickel, 2011, Urology.

Serum prostate specific antigen is a strong predictor of future prostate growth in men with benign prostatic hyperplasia. PROSCAR long-term efficacy and safety study.

P. Schellhammer, C. Roehrborn, M. Resnick, 2000, The Journal of urology.

The combination of histological prostate atrophy and inflammation is associated with lower risk of prostate cancer in biopsy specimens

G. Andriole, S. Freedland, D. Moreira, 2017, Prostate Cancer and Prostatic Diseases.

258: Baseline Body Mass Index (BMI) and the Development of Prostate Cancer (CAP) in the Medical Therapy of Prostatic Symptoms (Mtops) Trial

C. Roehrborn, M. Lucia, G. Andriole, 2005 .

Risks and benefits of repeated courses of intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer.

W. Catalona, G. Andriole, T. Ratliff, 1987, The Journal of urology.

Laparoscopic partial nephrectomy with a novel electrosurgical snare in a porcine model.

R. Clayman, D. Bostwick, A. Kibel, 2002, Journal of endourology.

159 PROSTATE CANCER RISK IN MEN WITH PROSTATE AND BREAST CANCER FAMILY HISTORY: RESULTS FROM THE REDUCE STUDY

Jianfeng Xu, G. Andriole, W. Isaacs, 2012 .

NFATc1 Promotes Prostate Tumorigenesis and Overcomes PTEN Loss-Induced Senescence

Matthew H Bailey, L. Ding, P. Humphrey, 2015, Oncogene.

Correlation of testicular color Doppler ultrasonography, physical examination and venography in the detection of left varicoceles in men with infertility.

G. Andriole, W. Middleton, J. Petros, 1991, Journal of Urology.

Acute scrotal disorders: prospective comparison of color Doppler US and testicular scintigraphy.

G. Andriole, B. Siegel, W. Middleton, 1990, Radiology.

Encephalopathy and an elevated serum aluminum level in a patient receiving intravesical alum irrigation for severe urinary hemorrhage.

L. Kavoussi, G. Andriole, L. D. Gelstein, 1986, The Journal of urology.

Inguinal mass in a 66-year-old man

H. Forman, R. Levitt, G. Andriole, 1992, Urologic radiology.

Dihydrotestosterone and the prostate: the scientific rationale for 5alpha-reductase inhibitors in the treatment of benign prostatic hyperplasia.

D. Tindall, C. Roehrborn, G. Andriole, 2004, The Journal of urology.

The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia

C. Roehrborn, G. Andriole, P. Walsh, 1998 .

Laparoscopic and Robotic Surgery of the Seminal Vesicles

G. Andriole, R. Figenshau, Eric H Kim, 2018, Smith's Textbook of Endourology.

Renal hypothermia achieved by retrograde endoscopic cold saline perfusion: technique and initial clinical application.

Ralph V Clayman, Jaime Landman, Chandru P Sundaram, 2003, Urology.

Indwelling double-J ureteral stents for temporary and permanent urinary drainage: experience with 87 patients.

J. Richie, G. Andriole, M. Bettmann, 1984, The Journal of urology.

Effect of increasing doses of saw palmetto extract on lower urinary tract symptoms: a randomized trial.

C. Roehrborn, E. Crawford, M. Barry, 2011, JAMA.

Identification of a novel susceptibility locus at 13q34 and refinement of the 20p12.2 region as a multi-signal locus associated with bladder cancer risk in individuals of European ancestry.

Zhaoming, Jack A. Taylor, L. Kiemeney, 2016, Human molecular genetics.

Unusual behavior of low-grade, low-stage transitional cell carcinoma of bladder.

J. Richie, G. Andriole, M. Garnick, 1985, Urology.

Safety and efficacy of an implantable leuprolide delivery system in patients with advanced prostate cancer.

G. Andriole, J. Gottesman, M. Soloway, 2000, The Journal of urology.

Management of Benign Prostatic Hyperplasia.

G. Andriole, Eric H Kim, Eric H. Kim, 2016, Annual review of medicine.

Laparoscopic gonadectomy in a case of testicular feminization.

R. Clayman, G. Andriole, E. McDougall, 1993, Urology.

Patterns of multiple recurrences of superficial (Ta/T1) transitional cell carcinoma of bladder and effects of clinicopathologic and biochemical factors

P. Humphrey, A. Kibel, G. Andriole, 2002, Cancer.

Long-term results after antegrade collagen injection for stress urinary incontinence following radical retropubic prostatectomy.

G. Andriole, C. Klutke, J. Klutke, 1999, Urology.

Surgeon's workshop: antegrade collagen injection: new technique for postprostatectomy stress incontinence.

G. Andriole, R. Nadler, C. Klutke, 1995, Journal of endourology.

Both acute and chronic inflammation are associated with less perineural invasion in men with prostate cancer on repeat biopsy

G. Andriole, S. Freedland, D. Moreira, 2018, BJU international.

The 19q12 bladder cancer GWAS signal: association with cyclin E function and aggressive disease.

M. Pike, J. Chang-Claude, E. Riboli, 2014, Cancer research.

Fine mapping of a region of chromosome 11q13 reveals multiple independent loci associated with risk of prostate cancer.

Peter Kraft, Nilanjan Chatterjee, Fredrik Wiklund, 2011, Human molecular genetics.

Liquid biomarkers for early detection of prostate cancer and summary of available data for their use in African-American men

G. Andriole, Eric H Kim, Grant M. Henning, 2022, Prostate Cancer and Prostatic Diseases.

Level-1 Data From the REDUCE Study and the PCPT Data

G. Andriole, G. Vemana, 2016 .

Identification of a new prostate cancer susceptibility locus on chromosome 8q24

Peter Kraft, Pär Stattin, Nilanjan Chatterjee, 2009, Nature Genetics.

Prostate-specific antigen density predicts adverse pathology and increased risk of biochemical failure.

A. Kibel, G. Andriole, S. Bhayani, 2006, Urology.

ACK1–AR and AR–HOXB13 signaling axes: epigenetic regulation of lethal prostate cancers

G. Andriole, K. Mahajan, N. Mahajan, 2020, NAR cancer.

Metformin Use and Risk of Prostate Cancer: Results from the REDUCE Study

G. Andriole, S. Freedland, D. Moreira, 2015, Cancer Prevention Research.

Making an imperfect marker better.

G. Andriole, S. Freedland, 2011, European urology.

Evolving understanding and categorization of prostate cancer: preventing progression to metastatic castration-resistant prostate cancer: RADAR IV.

E. Crawford, G. Andriole, S. Freedland, 2020, The Canadian journal of urology.

Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction

K. D. Sørensen, Ali Amin Al Olama, Lilit C Moss, 2021, Nature Genetics.

Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction

K. D. Sørensen, Ali Amin Al Olama, Lilit C Moss, 2021, Nature genetics.

Single-setting bilateral laparoscopic renal surgery: assessment of single-stage procedure.

G. Andriole, J. Landman, R. Figenshau, 2005, Urology.

Colorectal-cancer incidence and mortality with screening flexible sigmoidoscopy.

Mark P Purdue, Barnett S Kramer, John K Gohagan, 2012, The New England journal of medicine.

INCIDENCE OF BIOPSY-DETECTABLE PROSTATE CANCER IN THE REDUCTION BY DUTASTERIDE OF PROSTATE CANCER EVENTS (REDUCE) TRIAL: BLINDED 2-YEAR RESULTS

G. Andriole, M. Somerville, C. Teloken, 2009 .

Letters to the Editor/ErrataRE: EFFECT OF THE DUAL 5α-REDUCTASE INHIBITOR DUTASTERIDE ON MARKERS OF TUMOR REGRESSION IN PROSTATE CANCER

M. Gleave, J. Trachtenberg, G. Andriole, 2005 .

The dual 5-alpha-reductase inhibitor dutasteride induces atrophic changes and decreases relative cancer volume in human prostate.

D. Bostwick, K. Iczkowski, G. Andriole, 2005, Urology.

Analysis of Heritability and Shared Heritability Based on Genome-Wide Association Studies for Thirteen Cancer Types.

Jian Su, Wen Tan, Paolo Vineis, 2015, Journal of the National Cancer Institute.

Analysis of Heritability and Shared Heritability Based on Genome-Wide Association Studies for 13 Cancer Types

Alison P. Klein, William Wheeler, Li Jin, 2015 .

Genome-wide association study identifies multiple loci associated with bladder cancer risk.

William Wheeler, Paolo Vineis, Peter Kraft, 2014, Human molecular genetics.

Computed tomographic diagnosis of ureteral obstruction caused by a sloughed papilla

G. Andriole, R. Bahnson, 1988, Urologic radiology.

A common 8q24 variant in prostate and breast cancer from a large nested case-control study.

Peter Kraft, Jing Ma, Malcolm C Pike, 2007, Cancer research.

Chronic Baseline Prostate Inflammation is Associated with Lower Tumor Grade in Men with Prostate Cancer on Repeat Biopsy: Results from the REDUCE Study.

G. Andriole, S. Freedland, D. Moreira, 2020, The Journal of urology.

Baseline prostate atrophy is associated with lower tumor volume in men with prostate cancer on repeat biopsy

G. Andriole, S. Freedland, D. Moreira, 2017, Prostate Cancer and Prostatic Diseases.

Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array

Peter Kraft, Anssi Auvinen, Henrik Gronberg, 2013, Nature Genetics.

Fine-mapping identifies multiple prostate cancer risk loci at 5p15, one of which associates with TERT expression

Peter Kraft, Elaine A. Ostrander, Henrik Gronberg, 2013, Human molecular genetics.

Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants

K. D. Sørensen, Ali Amin Al Olama, H. Ostrer, 2018, Nature Communications.

Fine-Mapping the HOXB Region Detects Common Variants Tagging a Rare Coding Allele: Evidence for Synthetic Association in Prostate Cancer

D. Schaid, H. Brenner, R. Hayes, 2014, PLoS genetics.

Single-Nucleotide Polymorphism–Based Genetic Risk Score and Patient Age at Prostate Cancer Diagnosis

Jianfeng Xu, G. Andriole, W. Isaacs, 2019, JAMA network open.

A meta-analysis of genome-wide association studies to identify prostate cancer susceptibility loci associated with aggressive and non-aggressive disease.

Suzanne Chambers, Peter Kraft, Anssi Auvinen, 2013, Human molecular genetics.

Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Yeager M, Orr N, Hayes RB, Jacobs KB, Kraft

Paul Fearnhead, Brian Staats, Stephen J. Chanock, 2007 .

Prostate Cancer Early Detection Panel Members

P. Carroll, Ruth Etzioni, G. Andriole, 2015 .

Two Susceptibility Loci Identified for Prostate Cancer Aggressiveness

J. Witte, J. Carpten, H. Grönberg, 2015, Nature Communications.

Risk-based prostate cancer screening.

G. Andriole, A. Vickers, M. Roobol, 2012, European urology.

Role of active surveillance and focal therapy in low- and intermediate-risk prostate cancers

O. Cussenot, G. Andriole, C. Stief, 2015, World Journal of Urology.

Prostate Cancer Risk Reduction by Chemoprevention

A. Kibel, G. Andriole, K. Nepple, 2012 .

Effect of dutasteride on the risk of prostate cancer.

D. Tindall, D. Bostwick, T. Tammela, 2010, The New England journal of medicine.

Statin Use, Serum Lipids, and Prostate Inflammation in Men with a Negative Prostate Biopsy: Results from the REDUCE Trial

G. Andriole, S. Freedland, D. Moreira, 2017, Cancer Prevention Research.

A Case‐Crossover Study of Urological Chronic Pelvic Pain Syndrome Flare Triggers in the MAPP Research Network

Thomas O Jemielita, G. Colditz, G. Andriole, 2017, The Journal of urology.

Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017.

P. Kantoff, M. Cooperberg, T. Rebbeck, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The PREVAIL Study: Primary Outcomes by Site and Extent of Baseline Disease for Enzalutamide-treated Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer.

F. Saad, G. Andriole, K. Miller, 2016, European urology.

Quantitative trait loci predicting circulating sex steroid hormones in men from the NCI-Breast and Prostate Cancer Cohort Consortium ( BPC 3 )

Weinstein, M. Thun, R. Hayes, 2009 .

The Impact of Positron Emission Tomography with 18F-Fluciclovine on the Treatment of Biochemical Recurrence of Prostate Cancer: Results from the LOCATE Trial

D. Mankoff, G. Andriole, D. Schuster, 2019, The Journal of urology.

The utility of prostate‐specific antigen in the management of advanced prostate cancer

E. Crawford, G. Andriole, M. Garnick, 2013, BJU international.

Might Men Diagnosed with Metastatic Prostate Cancer Benefit from Definitive Treatment of the Primary Tumor? A SEER-Based Study

G. Andriole, 2014 .

Natural bladder filling alters resting brain function at multiple spatial scales: a proof-of-concept MAPP Network Neuroimaging Study

Richard E. Harris, V. Magnotta, G. Andriole, 2020, Scientific Reports.

A Prospective Study of Dietary Alpha-linolenic Acid and the Risk of Prostate Cancer (United States)

R. Hayes, G. Andriole, D. Reding, 2006, Cancer Causes & Control.

Androgen Deprivation Therapy for the Treatment of Prostate Cancer: Consider Both Benefits and Risks

G. Andriole, 2009 .

Assessing Electronic Capture of Patient Reported Outcomes in Prostate Cancer Populations

G. Andriole, L. McIntosh, A. Bullock, 2017 .

Acute Normovolemic Hemodilution Can Replace Preoperative Autologous Blood Donation as a Standard of Care for Autologous Blood Procurement in Radical Prostatectomy

W. Catalona, G. Andriole, L. Goodnough, 1997, Anesthesia and analgesia.

Renal autotransplantation in the management of a ureteroarterial fistula: a case report and review of the literature.

G. Andriole, G. Sicard, N. Neuman, 1992, Journal of vascular surgery.

NCCN Guidelines Insights: Prostate Cancer Early Detection, Version 2.2016.

P. Carroll, Ruth Etzioni, W. Lowrance, 2016, Journal of the National Comprehensive Cancer Network : JNCCN.

Prolonged diabetes insipidus subsequent to an episode of chemical meningitis.

G. Andriole, J. Vetto, J. Richie, 1986, Anesthesiology.

A prospective randomized comparison of three blood conservation strategies for radical prostatectomy.

W. Catalona, G. Andriole, L. Goodnough, 1999, Anesthesiology.

Erythropoietin therapy.

G. Andriole, L. Goodnough, T. Monk, 1997, The New England journal of medicine.

Gum Chewing Stimulates Bowel Motility in Patients Undergoing Radical Cystectomy with Urinary Diversion

G. Andriole, 2008 .

Preoperative oral rofecoxib does not decrease postoperative pain or morphine consumption in patients after radical prostatectomy: a prospective, randomized, double-blinded, placebo-controlled trial.

G. Andriole, A. Kurz, A. Taguchi, 2001, Journal of clinical anesthesia.

Prostate Cancer Early Detection, Version 2.2015

P. Carroll, Ruth Etzioni, W. Lowrance, 2015 .

Radiation therapy for increasing prostate-specific antigen levels after radical prostatectomy.

G. Andriole, J. Michalski, C. Perez, 2003, Clinical prostate cancer.

Danazol-induced cystitis: an undescribed source of hematuria in patients with hereditary angioneurotic edema.

G. Andriole, N. Javadpour, I. Sesterhenn, 1986, The Journal of urology.

Polymorphic variants in PTGS2 and prostate cancer risk: results from two large nested case-control studies.

Bingshu E. Chen, M. Thun, Jinbo Chen, 2007, Carcinogenesis.

Genetic Variation in the HSD17B1 Gene and Risk of Prostate Cancer

D. Altshuler, M. Pike, J. Hirschhorn, 2005, PLoS genetics.

Genetic Variation in the HSD 17 B 1 Gene and Risk of Prostate Cancer

D. Altshuler, M. Pike, J. Hirschhorn, 2005 .

Large-Scale Pathway-Based Analysis of Bladder Cancer Genome-Wide Association Data from Five Studies of European Background

Nilanjan Chatterjee, Neil E. Caporaso, Nathaniel Rothman, 2012, PloS one.

A genome-wide association study of bladder cancer identifies a new susceptibility locus within SLC14A1, a urea transporter gene on chromosome 18q12.3.

Jian Gu, Nilanjan Chatterjee, Jonine D Figueroa, 2011, Human molecular genetics.

Common genetic polymorphisms modify the effect of smoking on absolute risk of bladder cancer.

Nilanjan Chatterjee, Jonine D Figueroa, Margaret R Karagas, 2013, Cancer research.

Fine mapping and functional analysis of a common variant in MSMB on chromosome 10q11.2 associated with prostate cancer susceptibility

S. Weinstein, J. Ma, M. Thun, 2009, Proceedings of the National Academy of Sciences.

Sleep Problems are Associated with Development and Progression of Lower Urinary Tract Symptoms: Results from REDUCE

C. Roehrborn, G. Andriole, S. Freedland, 2018, The Journal of urology.

Diabetes and prostate cancer risk in the REDUCE trial

G. Andriole, S. Freedland, D. Moreira, 2011, Prostate Cancer and Prostatic Diseases.

A prospective study of meat and meat mutagens and prostate cancer risk.

Ulrike Peters, Rashmi Sinha, R. Sinha, 2005, Cancer research.

Transluminal repair of large intrarenal arteriovenous fistulas.

G. Andriole, M. Freeman, G. Sicard, 1988, The Journal of urology.

Cystotomy, temporary urinary diversion and bladder packing in the management of severe cyclophosphamide-induced hemorrhagic cystitis.

W. Catalona, G. Andriole, J. J. Yuan, 1990, The Journal of urology.

Diabetes mellitus and prostate cancer risk in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial

D. Albanes, G. Andriole, A. Schatzkin, 2008, Cancer Causes & Control.

Aspirin but not ibuprofen use is associated with reduced risk of prostate cancer: a PLCO Study

R. Hayes, G. Andriole, F. Shebl, 2012, British Journal of Cancer.

Characterizing Associations and SNP-Environment Interactions for GWAS-Identified Prostate Cancer Risk Markers—Results from BPC3

Peter Kraft, Jing Ma, Mattias Johansson, 2011, PloS one.

TNF polymorphisms and prostate cancer risk

Bingshu E. Chen, M. Thun, R. Hayes, 2008, The Prostate.

Endogenous sex hormones and the risk of prostate cancer: A prospective study

R. Hayes, N. Chatterjee, E. Crawford, 2007, International journal of cancer.

Prostate cancer specific survival in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.

H. Parnes, G. Andriole, D. Reding, 2012, Cancer epidemiology.

Prostate MRI: a national survey of Urologist’s attitudes and perceptions

Kathryn J Fowler, G. Andriole, B. Manley, 2016, International braz j urol : official journal of the Brazilian Society of Urology.

Prostate Cancer Screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: findings from the initial screening round of a randomized trial.

J. Gohagan, P. Prorok, B. Kramer, 2005, Journal of the National Cancer Institute.

Management of Symptom Flares and Patient-reported Flare Triggers in Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS)-Findings From One Site of the MAPP Research Network.

G. Colditz, G. Andriole, H. Lai, 2019, Urology.

Does Pollen Trigger Urologic Chronic Pelvic Pain Syndrome Flares? A Case-Crossover Analysis in the Multidisciplinary Approach to the Study of Chronic Pelvic Pain Research Network.

G. Colditz, G. Andriole, H. Lai, 2020, The Journal of urology.

Brain signature and functional impact of centralized pain: a multidisciplinary approach to the study of chronic pelvic pain (MAPP) network study

Richard E. Harris, G. Deutsch, G. Andriole, 2017, Pain.

Effect of Testosterone Supplementation on Functional Mobility, Cognition, and Other Parameters in Older Men: A Randomized Controlled Trial

G. Andriole, 2008 .

Large-scale fine mapping of the HNF1B locus and prostate cancer risk.

M. Thun, D. Gerhard, R. Hayes, 2011, Human molecular genetics.

Geographic Differences in Baseline Prostate Inflammation and Relationship with Subsequent Prostate Cancer Risk: Results from the Multinational REDUCE Trial

G. Andriole, S. Freedland, D. Moreira, 2018, Cancer Epidemiology, Biomarkers & Prevention.

Greater extent of prostate inflammation in negative biopsies is associated with lower risk of prostate cancer on repeat biopsy: results from the REDUCE study

G. Andriole, S. Freedland, D. Moreira, 2016, Prostate Cancer and Prostatic Diseases.

Evidence that lymphokine-activated killer cells and natural killer cells are distinct based on an analysis of congenitally immunodeficient mice.

G. Andriole, S. Rosenberg, J. Mulé, 1985, Journal of immunology.

A Prospective Adaptive Utility Trial to Validate Performance of a Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer in Patients with Prostate-specific Antigen 2-10ng/ml at Initial Biopsy.

P. Carroll, I. Thompson, G. Andriole, 2018, European urology.

A comprehensive analysis of common IGF1, IGFBP1 and IGFBP3 genetic variation with prospective IGF-I and IGFBP-3 blood levels and prostate cancer risk among Caucasians.

W. Willett, M. Thun, R. Hayes, 2010, Human molecular genetics.

Single-cell Spatial Proteomic Revelations on the Multiparametric MRI Heterogeneity of Clinically Significant Prostate Cancer

G. Andriole, J. Hsieh, J. Ippolito, 2021, Clinical Cancer Research.

Determination of the Role of Negative Magnetic Resonance Imaging of the Prostate in Clinical Practice: Is Biopsy Still Necessary?

Kathryn J Fowler, G. Andriole, R. Grubb, 2017, Urology.

Optimization of prostate biopsy - Micro-Ultrasound versus MRI (OPTIMUM): A 3-arm randomized controlled trial evaluating the role of 29 MHz micro-ultrasound in guiding prostate biopsy in men with clinical suspicion of prostate cancer.

M. Cooperberg, E. Crawford, F. Montorsi, 2021, Contemporary clinical trials.

Cognitive Versus Software Fusion for MRI-targeted Biopsy: Experience Before and After Implementation of Fusion.

Kathryn J. Fowler, Kathryn J Fowler, G. Andriole, 2018, Urology.

Final Results of a Phase I/II Multicenter Trial of WST11 Vascular Targeted Photodynamic Therapy for Hemi-Ablation of the Prostate in Men with Unilateral Low Risk Prostate Cancer Performed in the United States.

Leonard Marks, Mark Emberton, Jonathan Coleman, 2016, The Journal of urology.

Prostate cancer: to screen or not to screen?

G. Andriole, Gerald L Andriole, Alex Shteynshlyuger, 2009, The Urologic clinics of North America.

Extended mortality results for prostate cancer screening in the PLCO trial with median follow‐up of 15 years

J. Gohagan, P. Prorok, B. Kramer, 2017, Cancer.

Presence of Magnetic Resonance Imaging Suspicious Lesion Predicts Gleason 7 or Greater Prostate Cancer in Biopsy-Naive Patients.

Kathryn J Fowler, G. Andriole, Eric H Kim, 2016, Urology.

Follow‐up of Prostatectomy versus Observation for Early Prostate Cancer

T. Wilt, M. Barry, G. Andriole, 2017, The New England journal of medicine.

Use of Statins and the Risk of Death in Patients with Prostate Cancer

G. Andriole, 2014 .

Prostate-Specific Antigen in 2006 : Effective Use in Benign Prostatic Hyperplasia and Prostate Cancer

T. Skolarus, G. Andriole, 2006 .

Author Correction: Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci

K. D. Sørensen, Ali Amin Al Olama, H. Ostrer, 2019, Nature Genetics.

Association between race and follow‐up diagnostic care after a positive prostate cancer screening test in the Prostate, Lung, Colorectal, and Ovarian cancer screening trial

E. Crawford, G. Andriole, D. Penson, 2013, Cancer.

Development and Validity of a Silicone Renal Tumor Model for Robotic Partial Nephrectomy Training.

G. Andriole, R. Venkatesh, R. Figenshau, 2018, Urology.

Laparoscopic partial nephrectomy for renal masses: effect of tumor location.

Ralph V Clayman, Jaime Landman, Chandru P Sundaram, 2006, Urology.

EDITORIAL: BLADDER CANCER IN THE NEXT MILLENNIUM

G. Andriole, 1999 .

Pure laparoscopic radical heminephrectomy and partial isthmusectomy for renal cell carcinoma in a horseshoe kidney: case report and technical considerations.

G. Andriole, S. Bhayani, 2005, Urology.

Laparoscopic prostatectomy for prostate cancer: continued role in urology.

G. Andriole, K. Nepple, Y. Tanagho, 2013, Surgical oncology clinics of North America.

Managing the local complications of locally advanced prostate cancer

G. Andriole, R. Grubb, J. Anast, 2007 .

Managing the local complications of locally advanced prostate cancer

G. Andriole, R. Grubb, J. Anast, 2007, Current urology reports.

Hormonal manipulation for rising PSA after radical prostatectomy.

G. Andriole, S. Bhayani, 1999, Seminars in urologic oncology.

Prevention of benign prostatic hyperplasia disease.

Leonard S Marks, C. Roehrborn, G. Andriole, 2006, The Journal of urology.

Adjuvant therapy for prostate cancer patients at high risk of recurrence following radical prostatectomy.

G. Andriole, 1997, European urology.

443 NON-UROLOGICAL SYNDROMES AND SEVERITY OF UROLOGICAL PAIN SYMPTOMS: BASELINE EVALUATION OF THE NATIONAL INSTITUTES OF HEALTH MULTIDISCIPLINARY APPROACH TO PELVIC PAIN STUDY

David A. Williams, Alisa J. Stephens, G. Andriole, 2013 .

Testicular tumors: findings with color Doppler US.

G. Andriole, W. Middleton, G. Melson, 1992, Radiology.

Overview of pivotal studies for prostate cancer risk reduction, past and present.

G. Andriole, 2009, Urology.

Serum selenium and risk of prostate cancer-a nested case-control study.

R. Hayes, S. Chanock, N. Chatterjee, 2007, The American journal of clinical nutrition.

Individual Variations in Serum Melatonin Levels through Time: Implications for Epidemiologic Studies

Kai Yu, G. Andriole, T. Church, 2013, PloS one.

Sexually transmitted infections, benign prostatic hyperplasia and lower urinary tract symptom‐related outcomes: results from the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial

Stacey A. Kenfield, G. Andriole, L. Ragard, 2016, BJU International.

Interactions between genome-wide significant genetic variants and circulating concentrations of insulin-like growth factor 1, sex hormones, and binding proteins in relation to prostate cancer risk in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium.

R. Hayes, E. Riboli, S. Chanock, 2012, American journal of epidemiology.

Common Genetic Variants in Prostate Cancer Risk Prediction—Results from the NCI Breast and Prostate Cancer Cohort Consortium (BPC3)

Peter Kraft, Jing Ma, Mattias Johansson, 2012, Cancer Epidemiology, Biomarkers & Prevention.

Quantitative trait loci predicting circulating sex steroid hormones in men from the NCI-Breast and Prostate Cancer Cohort Consortium (BPC3).

M. Thun, R. Hayes, F. Clavel-Chapelon, 2009, Human molecular genetics.

Prostate cancer risk in men with prostate and breast cancer family history: results from the REDUCE study (R1)

Jianfeng Xu, G. Andriole, W. Isaacs, 2012, Journal of internal medicine.

Smoking and Prostate Cancer: A Systematic Review.

I. Thompson, G. Andriole, S. Freedland, 2015, European urology focus.

Effectiveness of postoperative radiotherapy after radical cystectomy for locally advanced bladder cancer

G. Andriole, T. Guzzo, V. Arora, 2019, Cancer medicine.

Smoking and Risk of Low- and High-Grade Prostate Cancer: Results from the REDUCE Study

Daniel Moreira, Leah Gerber, G. Andriole, 2014, Clinical Cancer Research.

Impact of childhood and recent traumatic events on the clinical presentation of overactive bladder

Clinton D. Morgan, G. Andriole, H. Lai, 2016, Neurourology and urodynamics.

Function and Aggressive Disease The 19 q 12 Bladder Cancer GWAS Signal : Association with Cyclin E Updated

Laurie, M. Pike, D. V. Berg, 2014 .

A genome-wide association study of bladder cancer identifies a new susceptibility locus within SLC 14 A 1 , a urea transporter gene on chromosome 18 q 12 . 3

M. Thun, N. Malats, M. Kogevinas, 2011 .

Dairy Products, Calcium Intake, and Risk of Prostate Cancer in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial

R. Hayes, N. Chatterjee, D. Albanes, 2007, Cancer Epidemiology Biomarkers & Prevention.

The effect of increasing doses of saw palmetto fruit extract on serum prostate specific antigen: analysis of the CAMUS randomized trial.

E. Crawford, M. Barry, G. Andriole, 2013, The Journal of urology.

Sexually transmitted diseases among users of erectile dysfunction drugs.

G. Andriole, I. Kawachi, E. Platz, 2010, Annals of internal medicine.

Perineal and bladder necrosis following bilateral internal iliac artery ligation report of a case

G. Andriole, P. Sugarbaker, Gerald L. Andriole, 1985, Diseases of the colon and rectum.

Delay of Radical Prostatectomy and Risk of Biochemical Progression in Men With Low Risk Prostate Cancer

G. Andriole, 2006 .

Prostate Cancer Mortality in the Finnish Randomized Screening Trial: Kilpeläinen TP, Tammela TL, Malila N, et al (Univ of Tampere, Finland; et al) J Natl Cancer Inst 105:719-725, 2013 §

G. Andriole, 2014 .

The prostate, lung, colon, and ovarian (PLCO) cancer screening trial: Status and promise.

John K Gohagan, J. Gohagan, P. Prorok, 2004, Urologic oncology.

A longitudinal analysis of urological chronic pelvic pain syndrome flares in the Multidisciplinary Approach to the Study of Chronic Pelvic Pain (MAPP) Research Network

G. Colditz, G. Andriole, J. Griffith, 2019, BJU international.

820 FREQUENCY AND DURATION SPECTRUM OF UROLOGIC CHRONIC PELVIC PAIN SYMPTOM FLARES

G. Colditz, G. Andriole, H. Lai, 2012 .

Prostate volume and prostate-specific antigen levels in men enrolled in a large screening trial.

J. Gohagan, B. Kramer, G. Andriole, 2006, Urology.

Common colorectal cancer risk alleles contribute to the multiple colorectal adenoma phenotype, but do not influence colonic polyposis in FAP

M. Thun, G. Colditz, S. Heath, 2014, European Journal of Human Genetics.

Population based comparative effectiveness of transurethral resection of the prostate and laser therapy for benign prostatic hyperplasia.

G. Andriole, K. Nepple, P. Owens, 2012, The Journal of urology.

Ascertaining cause of death among men in the Prostate Cancer Intervention Versus Observation Trial

T. Wilt, M. Barry, G. Andriole, 2013, Clinical trials.

Prophylactic Use of Antimicrobials in Commonly Performed Outpatient Urologic Procedures: Schaeffer EM (Johns Hopkins Med Institutions, Baltimore, Md) Nat Clin Pract Urol 3:24–31, 2006 §

G. Andriole, 2006 .

Repeat prostate biopsy in the Prostate, Lung, Colorectal and Ovarian cancer screening trial

J. Gohagan, B. Kramer, E. Crawford, 2007, BJU international.

Prostate cancer: A simplified prostate cancer grading system

G. Andriole, Eric H. Kim, 2015, Nature reviews. Urology.

DUROS [trade mark sign] LEUPROLIDE IMPLANTABLE THERAPEUTIC SYSTEMS IN PATIENTS WITH ADVANCED PROSTATE CANCER: 14-MONTH RESULTS OF A PHASE I/II DOSE-RANGING STUDY

G. Andriole, J. Gottesman, M. Soloway, 1999 .

Prostate cancer screening: current status and future perspectives

G. Andriole, S. Strope, 2010, Nature Reviews Urology.

Evaluation and management of the man who has failed primary curative therapy for prostate cancer.

D. Ornstein, G. Andriole, J. D. Herschman, 1998, The Urologic clinics of North America.

Clinical usefulness of serum prostate specific antigen for the detection of prostate cancer is preserved in men receiving the dual 5alpha-reductase inhibitor dutasteride.

C. Roehrborn, G. Andriole, M. Marberger, 2006, The Journal of urology.

PD31-01 METABOLIC SYNDROME COMPONENTS AND PROSTATE CANCER RISK: RESULTS FROM THE REDUCE STUDY

G. Andriole, S. Freedland, D. Moreira, 2014 .

C Update on chemoprevention for prostate cancer Strope and Andriole 195 Table 1 Risk of high-grade prostate cancer in the Prostate Cancer Prevention Trial after adjustment for bias against finasteride

G. Andriole, S. Strope, 2010 .

Statin use and longitudinal changes in prostate volume; results from the REduction by DUtasteride of prostate Cancer Events (REDUCE) trial

I. Csizmadi, C. Roehrborn, G. Andriole, 2019, BJU international.

Docetaxel Plus Prednisone or Mitoxantrone Plus Prednisone for Advanced Prostate Cancer: Updated Survival in the TAX 327 Study

G. Andriole, 2008 .

Prostate Cancer Risk in Men with Baseline History of Coronary Artery Disease: Results from the REDUCE Study

G. Andriole, S. Freedland, D. Moreira, 2012, Cancer Epidemiology, Biomarkers & Prevention.

1551: Transurethral Microwave Thermotherapy (TUMT) Using the Thermatrx TMX-2000™: Long-Term Results in a Study Comparing Tumt with a Sham Procedure in Patients with Benign Prostatic Hyperplasia (BPH)

J. Lingeman, G. Andriole, D. Albala, 2005 .

Metastatic prostate cancer at diagnosis and through progression in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial

R. Hoover, H. Parnes, G. Andriole, 2019, Cancer.

A phase I/II dose ranging study of DUROS (TM) (leuprolide) implantable therapeutic system in patients with advanced prostate cancer

G. Andriole, J. Gottesman, J. Libertino, 1998 .

Re: Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer: prostate specific antigen is superior to all other clinical parameters.

M. Becich, W. Catalona, G. Andriole, 1992, The Journal of urology.

Serum PSA after antiandrogen therapy.

G. Andriole, J. Petros, 1993, The Urologic clinics of North America.

Smoking Is Associated With Basal Cell Hyperplasia on Prostate Biopsy Specimens.

G. Andriole, S. Freedland, D. Moreira, 2021, American journal of clinical pathology.

Transrectal ultrasonography in the diagnosis and staging of carcinoma of the prostate.

L. Kavoussi, W. Catalona, G. Andriole, 1988, The Journal of urology.

Evaluation of a novel precision template‐guided biopsy system for detecting prostate cancer

A. Kibel, G. Andriole, S. Taneja, 2008, BJU international.

Relating biopsy and clinical variables to radical prostatectomy findings: can insignificant and advanced prostate cancer be predicted in a screening population?

Yan Yan, P. Humphrey, G. Andriole, 2004, Urology.

PSA predicts development of incident lower urinary tract symptoms: results from the REDUCE study

C. Roehrborn, G. Andriole, S. Freedland, 2018, Prostate Cancer and Prostatic Diseases.

Prostate cancer chemoprevention.

G. Andriole, K. Nepple, Y. Tanagho, 2013, Seminars in oncology.

Hormonal Manipulation of Benign Prostatic Hyperplasia

G. Andriole, 1991 .

OPERATING ROOM COST ANALYSIS: A SURVEY OF COST AWARENESS AMONG UROLOGIC SURGERY STAFF

T. Skolarus, G. Andriole, S. Bhayani, 2008 .

Baseline Subject Characteristics Predictive of Compliance with Study-Mandated Prostate Biopsy in Men at Risk of Prostate Cancer: Results from REDUCE

G. Andriole, S. Freedland, D. Moreira, 2015, Prostate Cancer and Prostatic Diseases.

Prostate‐specific antigen velocity and prostate cancer gleason grade and stage

J. Gohagan, E. Crawford, G. Andriole, 2007, Cancer.

Serum cholesterol and risk of high-grade prostate cancer: results from the REDUCE study

G. Andriole, S. Freedland, D. Moreira, 2017, Prostate Cancer and Prostatic Diseases.

Adjuvant Radiotherapy for Pathologically Advanced Prostate Cancer: A Randomized Clinical Trial

A. Kibel, G. Andriole, 2007 .

Influence of Local Tumor Control on Distant Metastases and Cancer Related Mortality After External Beam Radiotherapy for Prostate Cancer

G. Andriole, G. L. Andriole, 2008 .

Prostate cancer early detection, version 1.2014. Featured updates to the NCCN Guidelines.

P. Carroll, Ruth Etzioni, W. Lowrance, 2014, Journal of the National Comprehensive Cancer Network : JNCCN.

Prostate cancer early detection version 1

P. Carroll, Ruth Etzioni, W. Lowrance, 2014 .

Overdiagnosis of prostate cancer.

G. Andriole, G. Sandhu, 2012, Journal of the National Cancer Institute. Monographs.

Do Margins Matter? The Prognostic Significance of Positive Surgical Margins in Radical Prostatectomy Specimens

G. Andriole, G. L. Andriole, 2008 .

11C-acetate PET imaging of prostate cancer: detection of recurrent disease at PSA relapse.

Nobuyuki Oyama, Jeff M Michalski, Michael J Welch, 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

1176 SMOKING IS ASSOCIATED WITH ACUTE PROSTATIC INFLAMMATION IN MEN WITH A NEGATIVE PROSTATE BIOPSY: RESULTS FROM THE REDUCE STUDY

G. Andriole, S. Freedland, D. Moreira, 2013 .

Screening for cancer: lessons learned from the prostate, lung, colorectal, and ovarian cancer screening trial.

P. Prorok, G. Andriole, P. Pinsky, 2015, European urology.

Prostate specific antigen density versus prostate specific antigen slope as predictors of prostate cancer in men with initially negative prostatic biopsies.

W. Catalona, G. Andriole, Deborah S. Smith, 1996, The Journal of urology.

Secondary prostate cancer screening outcomes by race in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Screening Trial

Eric A. Miller, G. Andriole, P. Pinsky, 2018, The Prostate.

Defining the Problem

G. Andriole, K. Nepple, 2013 .

Prostate biopsy following a positive screen in the prostate, lung, colorectal and ovarian cancer screening trial.

Barnett S Kramer, John K Gohagan, J. Gohagan, 2005, The Journal of urology.

Impact of 18F-fluciclovine PET/CT on plans for androgen deprivation therapy in patients with biochemical recurrence of prostate cancer: data analysis from two prospective clinical trials.

G. Andriole, A. Scarsbrook, Bital Savir-Baruch, 2023, Urologic oncology.

Obesity, Serum Prostate Specific Antigen and Prostate Size: Implications for Prostate Cancer Detection

G. Andriole, 2006 .

The impact of systematic prostate biopsy on prostate cancer incidence in men with symptomatic benign prostatic hyperplasia undergoing transurethral resection of the prostate.

D. Ornstein, G. Andriole, Deborah S. Smith, 1997, The Journal of urology.

The ability of systematic transrectal ultrasound guided biopsy to detect prostate cancer in men with the clinical diagnosis of benign prostatic hyperplasia.

W. Catalona, G. Andriole, D. Coplen, 1991, The Journal of urology.

Nocturia and associated mortality: observational data from the REDUCE trial

G. Andriole, S. Freedland, D. Moreira, 2018, Prostate Cancer and Prostatic Diseases.

Prostate-specific antigen-based screening: controversy and guidelines

G. Andriole, Gerald L Andriole, Eric H Kim, 2015, BMC Medicine.

Application of a fixed retractor system to facilitate laparoscopic radical prostatectomy.

G. Andriole, R. Venkatesh, J. Landman, 2004, The Journal of urology.

The interpretation of serum prostate specific antigen in men receiving 5alpha-reductase inhibitors: a review and clinical recommendations.

C. Roehrborn, G. Andriole, J. Fitzpatrick, 2006, The Journal of urology.

Sleep quality and prostate cancer aggressiveness: Results from the REDUCE trial

G. Andriole, S. Freedland, D. Moreira, 2020, The Prostate.

The Association of Previous Prostate Biopsy Related Complications and the Type of Complication with Patient Compliance with Rebiopsy Scheme

G. Andriole, S. Freedland, D. Moreira, 2018, The Journal of urology.

Racial differences in prostate inflammation: results from the REDUCE study

G. Andriole, C. Drake, S. Freedland, 2016, Oncotarget.

Prostate specific antigen changes as related to the initial prostate specific antigen: data from the prostate, lung, colorectal and ovarian cancer screening trial.

J. Gohagan, B. Kramer, E. Crawford, 2006, The Journal of urology.

Long-term follow-up of men undergoing modified inguinal lymphadenectomy for carcinoma of the penis.

W. Catalona, G. Andriole, J. Colberg, 1997, British journal of urology.

Obesity and Capsular Incision at the Time of Open Retropubic Radical Prostatectomy

G. Andriole, 2006 .

EXTENT OF BASELINE PROSTATE ATROPHY IS ASSOCIATED WITH LOWER INCIDENCE OF LOW‐ AND HIGH‐GRADE PROSTATE CANCER ON REPEAT BIOPSY: MP20‐06

G. Andriole, S. Freedland, D. Moreira, 2017, Urology.

MP07-20 DISCOVERY, VALIDATION AND NOVEL VISUALIZATION OF SUBGROUPS IN UROLOGIC CHRONIC PELVIC PAIN SYNDROME (UCPPS)

M. Pontari, J. Farrar, G. Andriole, 2020 .

Evidence of Perineural Invasion on Prostate Biopsy Specimen and Survival After Radical Prostatectomy

G. Andriole, 2013 .

Fifth Joint Meeting of the American Urological Association and the Japanese Urological Association International Affiliate Society Meeting at the 105th Annual Meeting of the American Urological Association

J. Trachtenberg, G. Andriole, V. Margulis, 2010, International journal of urology : official journal of the Japanese Urological Association.

Prostate-specific antigen as a screening test for prostate cancer. The United States experience.

D. Ornstein, G. Andriole, G L Andriole, 1997, The Urologic clinics of North America.

Mean sojourn time, overdiagnosis, and reduction in advanced stage prostate cancer due to screening with PSA: implications of sojourn time on screening

G. Andriole, 2009 .

Antiadenovirus Antibodies Predict Response Durability to Nadofaragene Firadenovec Therapy in BCG-unresponsive Non–muscle-invasive Bladder Cancer: Secondary Analysis of a Phase 3 Clinical Trial

Anirban P. Mitra, G. Andriole, Y. Lotan, 2021, European Urology.

Prospective Multicenter Comparison of Open and Robotic Radical Prostatectomy: The PROST-QA/RP2 Consortium

John T. Wei, M. Cooperberg, P. Carroll, 2021, The Journal of urology.

Refining the Prostate Cancer Genetic Association within the JAZF1 Gene on Chromosome 7p15.2

M. Thun, H. Grönberg, R. Hayes, 2010, Cancer Epidemiology, Biomarkers & Prevention.

2D versus 3D visualization: impact on laparoscopic proficiency using the fundamentals of laparoscopic surgery skill set.

G. Andriole, Gerald L Andriole, Brian M Benway, 2012, Journal of laparoendoscopic & advanced surgical techniques. Part A.

Baseline Basal Cell Hyperplasia Is not Associated With Baseline Lower Urinary Tract Symptoms, Baseline Clinical Prostatitis or Prostate Cancer in Repeat Biopsies.

G. Andriole, S. Freedland, D. Moreira, 2019, Urology.

Tertiary Gleason Pattern 5 in Gleason 7 Prostate Cancer Predicts Pathological Stage and Biochemical Recurrence

G. Andriole, 2008 .

Improving prostate-specific antigen screening.

G. Andriole, S. Strope, Gerald L. Andriole, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The efficacy of prostate‐specific antigen screening: Impact of key components in the ERSPC and PLCO trials

E. Feuer, H. D. de Koning, Ruth Etzioni, 2018, Cancer.

The Association between Phosphodiesterase Type 5 Inhibitors and Prostate Cancer: Results from the REDUCE Study.

G. Andriole, S. Freedland, D. Moreira, 2016, The Journal of urology.

Safety and tolerability of the dual 5alpha-reductase inhibitor dutasteride in the treatment of benign prostatic hyperplasia.

G. Andriole, R. Kirby, 2003, European Urology.

Partial Validation of the Sleep Health Construct in the Medical Outcomes Study Sleep Questionnaire

G. Andriole, S. Freedland, D. Moreira, 2020, Journal of Clinical Psychology in Medical Settings.

Placebo-Controlled Phase III Trial of Immunologic Therapy with Sipuleucel-T (APC8015) in Patients with Metastatic, Asymptomatic Hormone Refractory Prostate Cancer: Small EJ, Schellhammer PF, Higano CS, et al (Univ of California San Francisco; Sharp Healthcare, San Diego, Calif; Eastern Virginia Med

G. Andriole, G. L. Andriole, 2007 .

Serum Prostate-Specific Antigen Hemodilution Among Obese Men Undergoing Screening in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial

P. Prorok, E. Crawford, C. Berg, 2009, Cancer Epidemiology Biomarkers & Prevention.

Prostate cancer diagnosis.

P. Humphrey, G. Andriole, Gerald L Andriole, 2010, Missouri medicine.

RNASEL Arg462Gln polymorphism and prostate cancer in PLCO

R. Hayes, N. Chatterjee, M. Yeager, 2007, The Prostate.

Author Correction: Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci

K. D. Sørensen, Ali Amin Al Olama, H. Ostrer, 2019, Nature Genetics.

Evaluation of Prostate Cancer

G. Andriole, R. Grubb, 2001 .

Prognostic Impact of Positive Surgical Margins in Surgically Treated Prostate Cancer: Multi-institutional Assessment of 5831 Patients

G. Andriole, G. L. Andriole, 2006 .

Prostate-Cancer Mortality at 11 Years of Follow-up: Schröder FH, for the ERSPC Investigators (Erasmus Univ Med Ctr, Rotterdam, The Netherlands; et al) N Engl J Med 366:981-990, 2012 §

G. Andriole, G. L. Andriole, 2012 .

Detection of High Grade Prostate Cancer among PLCO Participants Using a Prespecified 4‐Kallikrein Marker Panel

G. Andriole, A. Vickers, D. Sjoberg, 2017, The Journal of urology.

A Novel Antisense Oligonucleotide Inhibiting Several Antiapoptotic Bcl-2 Family Members Induces Apoptosis and Enhances Chemosensitivity in Androgen-Independent Human Prostate Cancer PC3 Cells

G. Andriole, 2006 .

Heavy ethanol intake and elevated prostate cancer risk among men with previous negative biopsies in the REDUCE trial.

G. Andriole, S. Freedland, D. Moreira, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Does the sequence of high-dose rate brachytherapy boost and IMRT for prostate cancer impact early toxicity outcomes? Results from a single institution analysis

G. Andriole, M. Altman, S. Goddu, 2021, Clinical and translational radiation oncology.

FURTHER ANALYSES FROM THE REDUCE PROSTATE CANCER RISK REDUCTION TRIAL

D. Tindall, D. Bostwick, T. Tammela, 2009 .

Catecholamine excess: Probable cause of postoperative tachycardia following retroperitoneal lymph node dissection (RPLND) for testicular carcinoma

R. Clayman, W. Catalona, G. Andriole, 1989, Journal of surgical oncology.

Serum prostate-specific antigen: expanding its role as a measure of treatment response in patients with prostate cancer.

G. Andriole, 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Genome-Wide Association Study of Prostate Cancer–Specific Survival

T. Sellers, D. Schaid, H. Brenner, 2015, Cancer Epidemiology, Biomarkers & Prevention.

Use of gelatin matrix to rapidly repair diaphragmatic injury during laparoscopy.

G. Andriole, S. Bhayani, R. Grubb, 2002, Urology.

Prostate cancer risk: overview of the disease, predictive factors, and potential targets for risk reduction. Introduction.

G. Andriole, 2009, Urology.

The Society of Urologic Oncology's reply to the US Preventative Services Task Force's recommendation on PSA testing.

P. Carroll, E. Messing, G. Andriole, 2012, Urologic oncology.

727Baseline characteristics of patients in the reduce chemoprevention study

G. Andriole, O. Brawley, R. Rittmaster, 2005 .

Lung cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.

D. Lynch, J. Gohagan, P. Prorok, 2010, Journal of the National Cancer Institute.

NCCN Clinical Practice Guidelines Prostate Cancer Early Detection, Version 2.2015.

P. Carroll, Ruth Etzioni, W. Lowrance, 2015, Journal of the National Comprehensive Cancer Network : JNCCN.

Long-term Outcomes of Salvage Lymph Node Dissection for Clinically Recurrent Prostate Cancer: Results of a Single-institution Series with a Minimum Follow-up of 5Years

G. Andriole, 2014 .

Screening in the randomized Prostate , lung , colorectal , and Ovarian ( PlcO ) cancer Screening trial

D. Lynch, J. Gohagan, P. Prorok, 2010 .

Measurement of prostate-specific antigen as a screening test for prostate cancer

S. Teutsch, W. Catalona, G. Andriole, 1991 .

The effect of finasteride in men with benign prostatic hyperplasia.

G. Andriole, P. Walsh, J. Imperato-McGinley, 1992, The Journal of urology.

Dutasteride Improves Nocturia but Does Not Lead to Better Sleep: Results from the REDUCE Clinical Trial

C. Roehrborn, G. Andriole, S. Freedland, 2021, The Journal of urology.

Novel non-MRI imaging techniques for primary diagnosis of prostate cancer: micro-ultrasound, contrast-enhanced ultrasound, elastography, multiparametric ultrasound, and PSMA PET/CT.

G. Andriole, S. Vourganti, M. Valerio, 2023, Prostate cancer and prostatic diseases.

Association of statin use with improved local control in patients treated with selective bladder preservation for muscle-invasive bladder cancer

G. Andriole, 2007 .

Smoking and Prostate Cancer: A Systematic Review.

I. Thompson, G. Andriole, S. Freedland, 2015, European urology focus.

Author Correction: Germline variation at 8q24 and prostate cancer risk in men of European ancestry

K. D. Sørensen, Ali Amin Al Olama, H. Ostrer, 2019, Nature Communications.

Racial differences in prostate inflammation: results from the REDUCE study

G. Andriole, C. Drake, S. Freedland, 2016, Oncotarget.

The Case for Prostate Cancer Screening with Prostate-Specific Antigen

G. Andriole, B. Djavan, N. Fleshner, 2006 .

The REDUCE Follow-Up Study: low rate of new prostate cancer diagnoses observed during a 2-year, observational, followup study of men who participated in the REDUCE trial.

G. Andriole, M. Manyak, R. Grubb, 2013, The Journal of urology.

Chemoprevention of Prostate Cancer

G. Andriole, S. Freedland, R. Hamilton, 2014 .

Economic analysis: Randomized, placebo-controlled clinical trial of dutasteride in men at high risk for prostate cancer

F. Montorsi, G. Andriole, L. Black, 2012 .

Periurethral transurethral microwave thermotherapy for the treatment of benign prostatic hyperplasia: an interim 1-year safety and efficacy analysis using the thermatrx TMx-2000.

J. Lingeman, G. Andriole, D. Albala, 2000, Techniques in urology.

P. Carroll, G. Andriole, A. Partin, 2018, European urology.

J. Trachtenberg, G. Andriole, V. Margulis, 2010, International journal of urology : official journal of the Japanese Urological Association.

Diabetes mellitus and prostate cancer risk in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial

D. Albanes, G. Andriole, A. Schatzkin, 2008, Cancer Causes & Control.

The PREVAIL Study: Primary Outcomes by Site and Extent of Baseline Disease for Enzalutamide-treated Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer.

F. Saad, G. Andriole, K. Miller, 2016, European urology.

The utility of prostate‐specific antigen in the management of advanced prostate cancer

E. Crawford, G. Andriole, M. Garnick, 2013, BJU international.

Effect of dutasteride on the risk of prostate cancer.

D. Tindall, D. Bostwick, T. Tammela, 2010, The New England journal of medicine.

Smoking and lower urinary tract symptoms in Reduction by Dutasteride of Prostate Cancer Events Trial

I. Csizmadi, G. Andriole, S. Freedland, 2023, The Prostate.

Nocturia and associated mortality: observational data from the REDUCE trial

G. Andriole, S. Freedland, D. Moreira, 2018, Prostate Cancer and Prostatic Diseases.

Alcohol intake increases high-grade prostate cancer risk among men taking dutasteride in the REDUCE trial.

G. Andriole, S. Freedland, J. Fowke, 2014, European urology.

The REDUCE Follow-Up Study: low rate of new prostate cancer diagnoses observed during a 2-year, observational, followup study of men who participated in the REDUCE trial.

G. Andriole, M. Manyak, R. Grubb, 2013, The Journal of urology.

Cost effectiveness of chemoprevention for prostate cancer with dutasteride in a high-risk population based on results from the REDUCE Clinical trial

M. Kattan, G. Andriole, L. Black, 2011, Applied health economics and health policy.

Biopsy misidentification identified by DNA profiling in a large multicenter trial.

G. Andriole, M. Somerville, R. Rittmaster, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Statin use and longitudinal changes in prostate volume; results from the REDUCE trial

I. Csizmadi, C. Roehrborn, G. Andriole, 2019 .

Economic analysis: Randomized, placebo-controlled clinical trial of dutasteride in men at high risk for prostate cancer

F. Montorsi, G. Andriole, L. Black, 2012 .

PET in Prostate and Bladder Tumors: Lee ST, Lawrentschuk N, Scott AM (Austin Hosp, Melbourne, Australia; Ludwig Inst for Cancer Res, Melbourne, Australia) Semin Nucl Med 42:231-246, 2012 §

G. Andriole, 2012 .

Prostate MRI: a national survey of Urologist’s attitudes and perceptions

Kathryn J Fowler, G. Andriole, B. Manley, 2016, International braz j urol : official journal of the Brazilian Society of Urology.

Contemporary Grading for Prostate Cancer: Implications for Patient Care

G. Andriole, 2013 .

Focal Therapy in Prostate Cancer: International Multidisciplinary Consensus on Trial Design

G. Andriole, 2014 .

Large-scale fine mapping of the HNF1B locus and prostate cancer risk.

M. Thun, D. Gerhard, R. Hayes, 2011, Human molecular genetics.

Can preoperative PSA doubling time and PSA velocity predict outcomes following radical prostatectomy?

G. Andriole, R. Grubb, 2006, Nature Clinical Practice Urology.

Prostate cancer early detection, version 1.2014. Featured updates to the NCCN Guidelines.

P. Carroll, Ruth Etzioni, W. Lowrance, 2014, Journal of the National Comprehensive Cancer Network : JNCCN.

Prostate cancer screening in the Prostate, Lung, Colorectal and Ovarian cancer screening trial: update on findings from the initial four rounds of screening in a randomized trial

J. Gohagan, P. Prorok, B. Kramer, 2008, BJU international.

Prostate cancer risk: overview of the disease, predictive factors, and potential targets for risk reduction. Introduction.

G. Andriole, 2009, Urology.

Prostate Cancer Screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: findings from the initial screening round of a randomized trial.

J. Gohagan, P. Prorok, B. Kramer, 2005, Journal of the National Cancer Institute.

Improvements in benign prostatic hyperplasia‐specific quality of life with dutasteride, the novel dual 5α‐reductase inhibitor

P. Boyle, G. Andriole, C. Roehrborn, 2003, BJU international.

Comparison of Training Modalities for Performing Laparoscopic Radical Prostatectomy: Experience With 1,000 Patients

G. Andriole, 2006 .

Changes in symptoms during urologic chronic pelvic pain syndrome symptom flares: Findings from one site of the MAPP Research Network

G. Colditz, G. Andriole, C. Bradley, 2015, Neurourology and urodynamics.

Obesity is associated with increased prostate growth and attenuated prostate volume reduction by dutasteride.

G. Andriole, S. Freedland, D. Moreira, 2013, European urology.

Dietary protein restriction reduces circulating VLDL triglyceride levels via CREBH-APOA5-dependent and -independent mechanisms.

G. Andriole, N. Veronese, L. Brace, 2018, JCI Insight.

Imputation and subset-based association analysis across different cancer types identifies multiple independent risk loci in the TERT-CLPTM1L region on chromosome 5p15.33.

David M. Thomas, Krista A. Zanetti, Geoffrey S. Tobias, 2014, Human molecular genetics.

Risk behaviours and benign prostatic hyperplasia

G. Andriole, D. Reding, D. Chia, 2004, BJU international.

Mortality results from a randomized prostate-cancer screening trial.

A. Miller, J. Gohagan, P. Prorok, 2009, The New England journal of medicine.

Impact of prostate-specific antigen testing on the clinical and pathological outcomes after radical prostatectomy for Gleason 8–10 cancers

G. Andriole, 2008 .

American Journal of Epidemiology Original Contribution Interactions between Genome-wide Significant Genetic Variants and Circulating Concentrations of Insulin-like Growth Factor 1, Sex Hormones, and Binding Proteins in Relation to Prostate Cancer Risk in the National Cancer Institute Breast and Pros

R. Hayes, S. Chanock, A. Tjønneland, 2022 .

Redesigning a large-scale clinical trial in response to negative external trial results: the CAMUS study of Phytotherapy for Benign Prostatic Hyperplasia

C. Roehrborn, G. Andriole, S. Kaplan, 2009, Clinical trials.

Screening by chest radiograph and lung cancer mortality: the Prostate, Lung, Colorectal, and Ovarian (PLCO) randomized trial.

J. Gohagan, P. Prorok, J. Rathmell, 2011, JAMA.

Radical Prostatectomy for Prostate Cancer

G. Andriole, 1994 .

Lung cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.

D. Lynch, J. Gohagan, P. Prorok, 2010, Journal of the National Cancer Institute.

The surgery of prostate cancer: An update of contemporary radical prostatectomy and brachytherapy series.

G. Andriole, J. S. Krumholtz, 1999, Seminars in surgical oncology.

Serum testosterone and dihydrotestosterone and prostate cancer risk in the placebo arm of the Reduction by Dutasteride of Prostate Cancer Events trial.

G. Andriole, S. Freedland, D. Moreira, 2012, European urology.

Germline variation at 8q24 and prostate cancer risk in men of European ancestry

K. D. Sørensen, H. Ostrer, T. Sellers, 2018, Nature Communications.

Symptom Variability and Early Symptom Regression in the MAPP Study: A Prospective Study of Urological Chronic Pelvic Pain Syndrome.

Thomas O Jemielita, Holly T. Sullivan, Alisa J. Stephens, 2016, The Journal of urology.

Active Surveillance for Clinically Localized Prostate Cancer—A Systematic Review

G. Andriole, 2014 .

Fine mapping and functional analysis of a common variant in MSMB on chromosome 10q11.2 associated with prostate cancer susceptibility

M. Thun, R. Hayes, S. Chanock, 2009, Proceedings of the National Academy of Sciences of the United States of America.

960 THE INFLUENCE OF A POSITIVE FAMILY HISTORY ON PROSTATE CANCER INCIDENCE AND DUTASTERIDE EFFICACY IN THE REDUCE STUDY

T. Tammela, G. Andriole, R. Castro, 2010 .